Analyst Rating Update on CEPHEID (CPHD)

CEPHEID (CPHD) : Zacks Investment Research ranks CEPHEID (CPHD) as 1, which is a Strong Buy recommendation. 6 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 other analysts are mildly bullish on the stock and favor a Buy. A total of 8 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 15 research analysts is 2.13, which indicates as a Buy.

CEPHEID (CPHD) : Currently there are 11 street experts covering CEPHEID (CPHD) stock. The most bullish and bearish price target for the stock is $47 and $28 respectively for the short term. The average price target of all the analysts comes to $37.73. The estimated standard deviation from the target is $5.85.

For the current week, the company shares have a recommendation consensus of Buy.


CEPHEID (NASDAQ:CPHD): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $35.94 and $35.86 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $37.30. The buying momentum continued till the end and the stock did not give up its gains. It closed at $36.80, notching a gain of 2.68% for the day. The total traded volume was 1,201,436 . The stock had closed at $35.84 on the previous day.

Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the clinical market and non-clinical markets. Its systems enable molecular testing for organisms and genetic-based diseases. Molecular testing involves various time-intensive steps, including sample preparation, DNA amplification and detection. The Companys systems integrate these steps and analyze biological samples in test cartridges. Its primary offering is the GeneXpert system, which integrates sample preparation in addition to DNA amplification and detection, serves reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals, as well as physician offices and other alternate site laboratories. It also offers the SmartCycler system, which integrates DNA amplification and detection to allow rapid analysis of a sample.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.